We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Vitamin D Deficiency Has Greater Risk for All-Cause Mortality

By LabMedica International staff writers
Posted on 18 Nov 2021
Print article
Image: The LIAISON XL is a fully automated chemiluminescence analyzer (Photo courtesy of DiaSorin)
Image: The LIAISON XL is a fully automated chemiluminescence analyzer (Photo courtesy of DiaSorin)
Observational epidemiological studies have consistently found that low concentrations of circulating 25-hydroxyvitamin D (25[OH]D), a metabolite used as a clinical indicator of vitamin D status, are associated with an increased risk of cardiovascular disease and all-cause mortality, as well as other chronic diseases.

An efficient approach for assessing the potential causal effect of vitamin D supplementation is Mendelian randomization. Mendelian randomization uses genetic variants specifically related to a particular exposure to compare genetically-defined population subgroups with different average levels of the exposure.

An international team of Medical Scientists in collaboration with and led by the University Hospital Würzburg (Wurzburg, Germany) undertook observational analyses using data from 33 prospective studies comprising 500,962 individuals with no known history of coronary heart disease or stroke at baseline. Mendelian randomization analyses were performed in four population-based cohort studies, comprising 386,406 middle-aged individuals of European ancestries, including 33,546 people who developed coronary heart disease, 18,166 people who had a stroke, and 27,885 people who died.

Primary outcomes were coronary heart disease, defined as fatal ischemic heart disease or non-fatal myocardial infarction; stroke, defined as any cerebrovascular disease; and all-cause mortality. The team measured concentrations of 25(OH)D in blood using the Liaison immunoassay analyser (DiaSorin; Saluggia, Italy) in the UK Biobank and Copenhagen studies, and liquid chromatography-tandem mass spectrometry in the EPIC-CVD study. In the Vitamin D Studies Collaboration (VitDSC), concentrations were measured by radioimmunoassay, direct chromatographic approaches, or other immunoassays. The team considered genetic variants from four gene regions previously shown to be strongly associated with 25(OH)D and implicated in the transport, metabolism, and synthesis of vitamin D: GC, DHCR7, CYP2R1, and CYP24A1. The GC gene encodes vitamin D binding protein.

The investigators reported that observational analyses suggested inverse associations between incident coronary heart disease, stroke, and all-cause mortality outcomes with 25(OH)D concentration at low 25(OH)D concentrations. In population-wide genetic analyses, there were no associations of genetically-predicted 25(OH)D with coronary heart disease, stroke, or all-cause mortality. However, for the participants with vitamin D deficiency (25[OH]D concentration <25 nmol/L), genetic analyses provided strong evidence for an inverse association with all-cause mortality (odds ratio [OR] per 10 nmol/L increase in genetically-predicted 25[OH]D concentration (0.69) and non-significant inverse associations for stroke (0.85) and coronary heart disease (0.89). A finer stratification of participants found inverse associations between genetically-predicted 25(OH)D concentrations and all-cause mortality up to around 40 nmol/L.

The authors concluded that they had found genetic evidence to suggest a causal relationship between 25(OH)D concentrations and mortality in individuals with low vitamin D status. The results have implications for the interpretation and design of vitamin D supplementation trials, and potential disease prevention strategies. The study was published on October 27, 2021in the journal The Lancet Diabetes & Endocrinology.

Related Links:
University Hospital Würzburg
DiaSorin


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more